Log in to search using one of your social media accounts:

 

KIT Mutations Linked to Imatinib Response in GIST KIT Mutations Linked to Imatinib Response in GIST
Different KIT mutations have various associations with the response of gastrointestinal stromal tumors (GISTs) to adjuvant imatinib, according to results from a Scandinavian Sarcoma Group multicenter trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 3, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Immunicum begins enrolment in Phase I/II trial of INTUVAX to treat GIST
Swedish-based biopharmaceutical company Immunicum has commenced enrolment in the Phase I/II clinical trial of INTUVAX for the treatment of patients with gastrointestinal stromal tumour (GIST). (Source: Drug Development Technology)
Source: Drug Development Technology - March 8, 2017 Category: Pharmaceuticals Source Type: news

Clinical Insights Into Gastrointestinal Stromal Tumours Clinical Insights Into Gastrointestinal Stromal Tumours
This study examined the treatment outcomes of GISTs, highlighting some of the diagnostic and therapeutic challenges.Frontline Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2017 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

Surgery May Be Preferable in Young Adults With GI Stromal Tumors Surgery May Be Preferable in Young Adults With GI Stromal Tumors
Young adults with gastrointestinal stromal tumors (GISTs) appear to fare best after undergoing operative treatment, according to a retrospective study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 26, 2017 Category: Surgery Tags: General Surgery News Source Type: news

Small intestine GIST associated with better prognosis in younger patients
Gastrointestinal stromal tumors (GIST) are tumors that arise is the wall of the digestive tract, and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults (AYA) under 40 years old as well. Researchers report findings from the first population-based analysis of AYA patients with GIST. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 18, 2017 Category: Science Source Type: news

Small intestine GIST associated with better prognosis in younger patients
(University of California - San Diego) Gastrointestinal stromal tumors (GIST) are tumors that arise is the wall of the digestive tract, and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults (AYA) under 40 years old as well. Researchers at the University of California San Diego School of Medicine report findings from the first population-based analysis of AYA patients with GIST. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 18, 2017 Category: Global & Universal Source Type: news

Wedge Resection Apt for Gastrointestinal Stromal Tumors Wedge Resection Apt for Gastrointestinal Stromal Tumors
With appropriate selection and on-table gastroscopy when needed, laparoscopic nonanatomic wedge resection can deal with most gastric gastrointestinal stromal tumors (GISTs), according to Canadian researchers.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 24, 2016 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Small GISTs More Deadly Than Previously ThoughtSmall GISTs More Deadly Than Previously Thought
Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 14, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Detecting BRAF V600E-Mutated Gastrointestinal Stromal TumorsDetecting BRAF V600E-Mutated Gastrointestinal Stromal Tumors
The authors evaluated the utility of a BRAF V600E mutant-specific monoclonal antibody in the detection of BRAF-mutated GISTs. American Journal of Clinical Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 24, 2015 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Microbes evolve faster than ocean can disperse them
Scientists have created an advanced model aimed at exploring the role of neutral evolution in the biogeographic distribution of ocean microbes. Over the past sev­eral decades, ecol­o­gists have come to under­stand that both natural selec­tion and neu­tral evolution -- that vari­a­tion within and between species is caused by genetic drift and random mutations -- play a role in the bio­geo­graphic pat­terns of ocean microbes. New results flew in the face of the long held notion that microbes are infi­nitely mobile. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 11, 2014 Category: Science Source Type: news

Darker origin behind the kindly act of fairness
We often think of playing fair as an altru­istic behavior. We're sac­ri­ficing our own poten­tial gain to give others what they deserve. What could be more self­less than that? But new research from North­eastern Uni­ver­sity assis­tant pro­fessor of phi­los­ophy Rory Smead sug­gests another, darker origin behind the kindly act of fairness.Smead studies spite. It's a conun­drum that evo­lu­tionary biol­o­gists and behav­ioral philoso­phers have been mulling over for decades, and it's still rel­a­tively unclear why the seem­ingly poi...
Source: Health News from Medical News Today - March 11, 2014 Category: Consumer Health News Tags: Psychology / Psychiatry Source Type: news

Bayer gets Health Canada approval for treatment of GIST with Stivarga
German pharmaceutical firm Bayer has received approval from Health Canada for its Stivarga (regorafenib tablets) to treat adult patients with metastatic and unresectable gastrointestinal stromal tumours (GIST). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 20, 2013 Category: Pharmaceuticals Source Type: news

Intelligence Agents More Likely To Make Irrational Decisions Compared To College Students
A study conducted at Cornell University reveals that U.S. intelligence agents are more likely to make irrational decision-making biases compared to college students. The finding was published in the journal Psychological Science. When people get older they start to make changes in their decision-making; decisions are made less analytically and are more based on gists (according to the Fuzzy-trace theory.) "FTT [Fuzzy-trace theory] makes the counterintuitive prediction that reliance on gist-based thinking increases with development... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 10, 2013 Category: Consumer Health News Tags: Psychology / Psychiatry Source Type: news

Newspath June 2013 - Gastrointestinal Stromal Tumors
Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors almost exclusively occurring along the GI tract. (Source: NewsPath - Pathology News for the Medical Community)
Source: NewsPath - Pathology News for the Medical Community - June 4, 2013 Category: Pathology Source Type: news

Tool Could Help Discover New Compounds, Combinations; Quickly Identify Most Effective Gastrointestinal Stromal Tumor Treatments
A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, according to new findings presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2013 Category: Consumer Health News Tags: GastroIntestinal / Gastroenterology Source Type: news

Horizon scanning: US FDA approves regorafenib for advanced gastrointestinal stromal tumors
Source: US FDA Area: News The U.S. Food and Drug Administration (FDA) has approved regorafenib (Stivarga) for the treatment of patients with advanced gastrointestinal stromal tumours (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease - imatinib and sunitinib.   The approval is based on the results of the GRID trial, previously reported on the NeLM in November 2012 - please see link below details. (Source: NeLM - News)
Source: NeLM - News - February 26, 2013 Category: Drugs & Pharmacology Source Type: news

Endoscopic Submucosal Dissection of Large GISTsEndoscopic Submucosal Dissection of Large GISTs
This study takes a close look at endoscopic submucosal dissection and its outcome in patients. Journal of Gastroenterology and Hepatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 20, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news